BofA analyst Lisa Lewandowski raised the firm’s price target on Cronos Group to $2 from $1.78 and keeps an Underperform rating on the shares. The analyst updated the price target to reflect the firm’s refreshed sales estimates and a shift to 2025 valuations. The firm continues to see downside risk to the stock’s valuation saying Cronos continues to overspend relative to its size and Canadian cannabis industry conditions.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRON:
- Rising High: Exclusive talk with biotech company Tryp Therapeutics
- Premium Cannabis Brand Lord Jones® Launches Live Resin Vapes
- Cronos Group announces launch of Lord Jones Live Resin Vapes
- Rising High: Exclusive talk with cannabis REIT NewLake Capital
- Here’s What You Missed in Cannabis, Psychedelics This Week
